Approval · Notice of Compliance 18564 · 2016
REOPRO: Notice of Compliance 18564
Issued October 13, 2016
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18564
- Date
- October 13, 2016
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Labelling Only
- Reason
- Administrative - Transfer of Drug Identification Number (DIN); Labelling Updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| REOPRO | Not yet assigned | — |
Medicinal ingredients
- ABCIXIMAB 2 MG per ML